VVOS Vivos Therapeutics Inc

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

(RULE 14a-101)

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

☐	Preliminary Proxy Statement
☐	Confidential, For Use of the Commission Only (As Permitted by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☒	Definitive Additional Materials
☐	Soliciting Material under Rule 14a-12

 

VIVOS THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

☒	No fee required
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

(1) Title of each class of securities to which transaction applies:

 

(2) Aggregate number of securities to which transaction applies:

 

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

(4) Proposed maximum aggregate value of transaction:

 

(5) Total fee paid:

 

☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

 

(1) Amount Previously Paid:

 

(2) Form, Schedule or Registration Statement No.:

 

(3) Filing Party:

 

(4) Date Filed:

 

 

 

 

Vivos Therapeutics, Inc.

Supplemental Proxy Materials
For the Annual Meeting of Stockholders

On Friday, September 22, 2023

 

September 14, 2023

 

Re: VIVOS THERAPEUTICS – ANNUAL MEETING: SEPTEMBER 22, 2023

 

Dear Stockholder:

 

Vivos Therapeutics, Inc. has retained Laurel Hill Advisory Group to assist with the solicitation of proxies from stockholders for the Annual Meeting to be held on Friday, September 22, 2023. Attached is the most recent shareholder communication which can also be found at the following link:

 

https://www.sec.gov/Archives/edgar/data/1716166/000149315223031882/formdefa14a.htm

 

The meeting is one week away and to date, your proxy vote has not been received. Kindly take the time to vote your shares online as soon as practicable: https://ts.vstocktransfer.com/pxlogin. Please click on Proxy Voter Login and log on using the control number that was imprinted on your proxy card. If you need your control number, please email: info@laurelhill.com and reference Vivos Therapeutics. Your vote is important, regardless of the number of shares you own.

 

If you have any questions or need assistance with your vote, please feel free to call 888-742-1305.

 

Thank you.

 

---